El Impacto sobre la función sexual en hombres con cáncer de mama: revisión de alcance
Article Sidebar
Publicado
sep 28, 2023
##plugins.pubIds.doi.readerDisplayName##
https://doi.org/10.36677/medicinainvestigacion.v11i2.21211
Main Article Content
Yuliana Vera-Alanis, PhD.
http://orcid.org/0000-0002-4905-1939
Guillermo Cano-Verdugo, PhD.
http://orcid.org/0000-0002-8523-2630
http://orcid.org/0000-0002-4905-1939
Guillermo Cano-Verdugo, PhD.
http://orcid.org/0000-0002-8523-2630
Resumen
Introducción: El cáncer de mama en hombres es una enfermedad poco frecuente que trae consecuencias directas relacionadas con la calidad de vida, la apariencia física y la función sexual. El objetivo fue sintetizar la información sobre la función sexual en hombres con cáncer de mama.
Materiales y métodos: Se realizó una revisión de alcance mediante la búsqueda de información disponible en las bases de datos PubMed, DOAJ, Scientific Research Publishing y National Library of Medicine. Se utilizaron conceptos relacionados con el cáncer de mama en hombres y la función sexual. Se identificaron 73 artículos y se seleccionaron 25.
Resultados: El análisis identificó cuatro tipos de repercusiones del cáncer de mama con respecto a la sexualidad: a nivel de actividad sexual, a nivel corporal, a nivel hormonal y a nivel socioemocional. Se encontró que tanto el diagnóstico como su tratamiento, especialmente el tamoxifeno, provocan disminución o ausencia de deseo sexual, disfunción eréctil, inflamación y dolor de la mama afectada, retracción y supuración del pezón, alteraciones del estado de ánimo, depresión y masculinidad afectada.
Conclusiones: Los hombres con cáncer de mama presentan condiciones adversas relacionadas con su patología y tratamiento que pueden reducir su función sexual y su calidad de vida.
Article Details
Como citar
VERA-ALANIS, Yuliana; CANO-VERDUGO, Guillermo.
El Impacto sobre la función sexual en hombres con cáncer de mama: revisión de alcance.
Medicina e Investigación Universidad Autónoma del Estado de México, [S.l.], v. 11, n. 2, p. 77-85, sep. 2023.
ISSN 2594-0600.
Disponible en: <https://medicinainvestigacion.uaemex.mx/article/view/21211>. Fecha de acceso: 18 ago. 2026
doi: https://doi.org/10.36677/medicinainvestigacion.v11i2.21211.
Sección
Artículos de revisión
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
Citas
Liu D, Xie G, Chen M. Clinicopathologic characteristics and survival of male breast cancer. International Journal of Clinical Oncology. 2013; 19 (2): 280–7. https://doi.org/10.1007/s10147-013-0555-4
Egestad LK, Gyldenvang HH, & Jarden M. “My Husband Has Breast Can-cer”: A Qualitative Study of Experiences of Female Partners of Men With Breast Cancer. Cancer Nurs. 2020; 43: 366–374. https://doi.org/10.1097/NCC.0000000000000710
Midding E, Halbach SM, Kowalski C, Weber R, Würstlein R, & Ernstmann N. Men With a “Woman’s Disease”: Stigmatization of Male Breast Cancer Pa-tients-A Mixed Methods Analysis. Am J Mens Health. 2018; 12: 2194–2207. https://doi.org/10.1177/1557988318799025
Rowland E, & Metcalfe A. A systematic review of men’s experiences of their partner’s mastectomy: coping with altered bodies. Psychooncology. 2014; 23: 963–974. https://doi.org/10.1002/pon.3556
Lantz SE, Ray S. Freud Developmental Theory. Treasure Island FL: Stat Pearls Publishing; 2022.
Pemmaraju N, Munsel, MF, Hortobagyi GN, Giordano SH. Retrospective re-view of male breast cancer patients: analysis of tamoxifen-related side-ef-fects. Ann Onc. 2012; 23: 1471-1474. https://doi.org/10.1093/annonc/mdr459
Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F. Male breast cancer: a disease distinct from fe-male breast cancer. Breast Cancer Res Treat. 2019; 173: 37–48. https://doi.org/10.1007/s10549-018-4921-9
Kalra G, Ventriglio A, Bhugra D. Sexualidad y salud mental: ¿Temas y qué sigue?. Int Rev Psychiatry. 2015; 27: 463-469. https://doi.org/10.3109/09540261.2015.1094032
Leone JP, Leone J, Zwenger AO, Iturbe J, Vallejo CT, Leone BA. Prognostic significance of tumor subtypes in male breast cancer: a population-based study. Breast Cancer Res Treat. 2015; 152: 601–609. https://doi.org/10.1007/s10549-015-3488-
Petridou E, Giokas G, Kuper H, Mucci LA, Trichopoulos D. Endocrine corre-lates of male breast cancer risk: a case-control study in Athens, Greece. Br J Cancer. 2000; 83: 1234-1237. doi:10.1054/bjoc.2000.1467
Petridou E, Giokas G, Kuper H, Mucci LA, Trichopoulos D. Endocrine corre-lates of male breast cancer risk: a case-control study in Athens, Greece. Br J Cancer. 2000; 83: 1234-1237. doi:10.1054/bjoc.2000.1467
Tricco A, Erin Lilli, Wasifa Zarin. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018; 169: 467-473. https://doi.org/10.7326/m18-0850
Gennari R, Curigliano G, Jerec-zek-Fossa BA, Zurrida S, Renne G, Intra M, Galimberti V, Luini A, Orecchia R, Viale G, Goldhrisch A, Veronesi U. Male breast cancer: a special therapeutic problem. Anything new? (Review). Int J On-col. 2004; 24: 663–670. Pubmed PMID: 14767551
Motofei IG, Rowland DL, Pop F, Bra-tucu E, Straja D, Manea M, Constan-tin VD. A Pilot Study on Tamoxifen Sexual Side Effects and Hand Pre-ference in Male Breast Cancer. Arch Sex Behav. 2015; 44: 1589–1594. doi:10.1007/s10508-015-0530-4
Bootsma TI, Duijveman P, Pijpe A, Scheelings PC, Witkamp AJ, Bleike, EM. Unmet information needs of men with breast cancer and heal-th professionals. Psychooncolo-gy. 2020; 29: 851-860. https://doi.org/10.1002/pon.5356
Duso BA, Trapan D, Marra A, D’Amico P, Guerini Rocco E, Fus-co N, Mazzarella L, Criscitiello C, Esposito A, Curigliano G. Pharma-cological management of male breast cancer. Expert Opin Phar-macother. 2020; 21: 1493–1504. https://doi.org/10.1080/14656566.2020.1763305
Lewis-Smith, H. Breast cancer or chest cancer? The impact of li-ving with a “woman’s disease”. J aesthet nurs. 2016; 5: 240–241. doi:10.12968/joan.2016.5.5.240
Reinisch M, Seiler S, Hauzenberger T, Kamischke A, Schmatloch S, Stri-ttmatter HJ, Loibl S. Efficacy of endocrine therapy for the treatment of breast cancer in men: results from the MALE phase 2 randomized clinical trial. JAMA Oncol. 2021; 7: 565-572. https://doi.org/10.1001/jamaoncol.2020.7442
Sang G, Pan H, Lu C, Sun R, Zha X, Wang S, Zhu D. Clinical features and prognostic factors of male breast cancer vs. female breast cancer. Transl Cancer Res. 2021; 10: 2199–2209. https://doi.org/10.21037/tcr-21-1
Wibowo E, Pollock PA, Hollis N, Wassersug RJ. Tamoxifen in men: a re-view of adverse events. Andrology. 2016; 4: 776–788. https://doi.org/10.1111/andr.12197
Kim SH, Kim YS. Ultrasonographic and Mammographic Findings of Male Breast Disease. J Ultrasound. 2019; 38: 243–252. https://doi.org/10.1002/jum.14665
Ruddy K, Ferzoco R. Optimal delivery of male breast cancer follow-up care: improving outcomes. Breast Cancer: Targets Ther. 2015; 14: 371. doi:10.2147/bctt.s75630
Thompson E, Haydock A. Men’s Lived Experiences with Breast Cancer: The Double Consciousness of Marginal Men. Sex Roles. 2019; 82: 28–43. doi:10.1007/s11199-019-01039-7
Darkeh MHSE, Azavedo E. Male breast cancer clinical features, risk factors, and current diagnostic and therapeutic approaches. Int J Clin Med. 2014; 5: 1068–1086. http://dx.doi.org/10.4236/ijcm.2014.517138
Hwang EJ, Cha JH. [A Review on Gynecomastia and Male Breast Cancer for Radiologists]. J Korean Soc Radio. 2020; 81: 1096–1108. https://doi.org/10.3348/jksr.2019.0203
Eggemann H, Brucker C, Schrauder M, Thill M, Flock F, Reinisch M, Costa SD, Ignatov A. Survival benefit of tamoxifen in male breast cancer: prospec-tive cohort analysis. Br J Cancer. 2020; 123: 33–37. https://doi.org/10.1038/s41416-020-0857-z
Jain S, Gradishar WJ. Male breast cancer. Evanston: Elsevier; 2018.28. Leon-Ferre RA, Giridhar KV, Hieken TJ, Mutter RW, Couch FJ, Jimenez RE, Ruddy KJ. A contemporary review of male breast cancer: current eviden-ce and unanswered questions. Cancer Metastasis Rev. 2018; 37: 599-614. doi:10.1007/s10555-018-9761-x
Sabih QA, Young J, Takabe K. Management of Male Breast Cancer: The Journey so Far and Future Directions. World J Oncol. 2021; 12: 206–213. https://doi.org/10.14740/wjon1418
Charalambous A, Giannakopoulou M, Bozas E, Paikousis L. Parallel and se-rial mediation analysis between pain, anxiety, depression, fatigue and nau-sea, vomiting and retching within a randomised controlled trial in patients with breast and prostate cancer. BMJ Open. 2019; 9: e026809. https://doi.org/10.1136/bmjopen-2018-026809
Nikolić D, Granić M, Ivanović N, Zdravković D, Nikolić A, Stanimirović V, Zdravković M, Dikić S, Nikolić M, Djordjević M. Breast cancer and its impact in male transsexuals. Breast Cancer Res Treat. 2018; 171: 565–569. https://doi.org/10.1007/s10549-018-4875-y
Walker RK, Ehrlich O, Berry DL. Male breast cancer survivors’ pers-pectives on the adequacy of their survivorship care. Innovation in Aging. 2018; 1: (2): 418–8. https://doi:10.1093/geroni/igy023.1563
American Cancer Society. Cómo el cáncer y el tratamiento pueden afec-tar la sexualidad. Am Can Soc [serial on the Internet].2020 Jan-Mar [cited 2022 Nov 5]; 1 (1): [about 24 p.]. Avai-lable from: https://www.cancer.org/es/tratamiento/tratamientos-y-efectos-se-cundarios/efectos-secundarios-fisicos/efectos-secundarios-sobre-la-ferti-lidad-y-la-sexualidad/como-el-can-cer-afecta-la-sexualidad.html
Campo-Arias A, Herazo E. Noveda-des, críticas y propuestas al DSM-5: el caso de las disfunciones sexua-les, la disforia de género y los tras-tornos parafílicos. Rev Colomb Psi-quiatr. 2016;47:56-64. doi:10.1016/j.rcp.2016.08.008.
Marina P, García-Portilla MP, Jimé-nez L, Palicioc L, Trabajo P, Bobes J. Función sexual en pacientes de-primidos: Relación entre síntomas depresivos y disfunción sexual. Rev Neuropsiquiátr. 2013; 76: 3.
Bettahar K, Pinton A. Agonistas de la hormona liberadora de gonadotropi-nas (GnRH). EMC - Ginecología-Obs-tetricia. 2019; 55: 1-9. https://doi.org/10.1016/S1283-081X(19)42001-8.
Oncology Nurse Advisor. Optimal De-livery of Male Breast Cancer Follow-up Care: Improving Outcomes [Internet]. Oncology Nurse Advisor. 2015 [cited 2023 Mar 14]. Available from: https://www.oncologynurseadvisor.com/home/cancer-types/breast-cancer/optimal-delivery-of-male-breast-can-cer-follow-up-care-improving-outco-mes/4/
Egestad LK, Gyldenvang HH, & Jarden M. “My Husband Has Breast Can-cer”: A Qualitative Study of Experiences of Female Partners of Men With Breast Cancer. Cancer Nurs. 2020; 43: 366–374. https://doi.org/10.1097/NCC.0000000000000710
Midding E, Halbach SM, Kowalski C, Weber R, Würstlein R, & Ernstmann N. Men With a “Woman’s Disease”: Stigmatization of Male Breast Cancer Pa-tients-A Mixed Methods Analysis. Am J Mens Health. 2018; 12: 2194–2207. https://doi.org/10.1177/1557988318799025
Rowland E, & Metcalfe A. A systematic review of men’s experiences of their partner’s mastectomy: coping with altered bodies. Psychooncology. 2014; 23: 963–974. https://doi.org/10.1002/pon.3556
Lantz SE, Ray S. Freud Developmental Theory. Treasure Island FL: Stat Pearls Publishing; 2022.
Pemmaraju N, Munsel, MF, Hortobagyi GN, Giordano SH. Retrospective re-view of male breast cancer patients: analysis of tamoxifen-related side-ef-fects. Ann Onc. 2012; 23: 1471-1474. https://doi.org/10.1093/annonc/mdr459
Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F. Male breast cancer: a disease distinct from fe-male breast cancer. Breast Cancer Res Treat. 2019; 173: 37–48. https://doi.org/10.1007/s10549-018-4921-9
Kalra G, Ventriglio A, Bhugra D. Sexualidad y salud mental: ¿Temas y qué sigue?. Int Rev Psychiatry. 2015; 27: 463-469. https://doi.org/10.3109/09540261.2015.1094032
Leone JP, Leone J, Zwenger AO, Iturbe J, Vallejo CT, Leone BA. Prognostic significance of tumor subtypes in male breast cancer: a population-based study. Breast Cancer Res Treat. 2015; 152: 601–609. https://doi.org/10.1007/s10549-015-3488-
Petridou E, Giokas G, Kuper H, Mucci LA, Trichopoulos D. Endocrine corre-lates of male breast cancer risk: a case-control study in Athens, Greece. Br J Cancer. 2000; 83: 1234-1237. doi:10.1054/bjoc.2000.1467
Petridou E, Giokas G, Kuper H, Mucci LA, Trichopoulos D. Endocrine corre-lates of male breast cancer risk: a case-control study in Athens, Greece. Br J Cancer. 2000; 83: 1234-1237. doi:10.1054/bjoc.2000.1467
Tricco A, Erin Lilli, Wasifa Zarin. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018; 169: 467-473. https://doi.org/10.7326/m18-0850
Gennari R, Curigliano G, Jerec-zek-Fossa BA, Zurrida S, Renne G, Intra M, Galimberti V, Luini A, Orecchia R, Viale G, Goldhrisch A, Veronesi U. Male breast cancer: a special therapeutic problem. Anything new? (Review). Int J On-col. 2004; 24: 663–670. Pubmed PMID: 14767551
Motofei IG, Rowland DL, Pop F, Bra-tucu E, Straja D, Manea M, Constan-tin VD. A Pilot Study on Tamoxifen Sexual Side Effects and Hand Pre-ference in Male Breast Cancer. Arch Sex Behav. 2015; 44: 1589–1594. doi:10.1007/s10508-015-0530-4
Bootsma TI, Duijveman P, Pijpe A, Scheelings PC, Witkamp AJ, Bleike, EM. Unmet information needs of men with breast cancer and heal-th professionals. Psychooncolo-gy. 2020; 29: 851-860. https://doi.org/10.1002/pon.5356
Duso BA, Trapan D, Marra A, D’Amico P, Guerini Rocco E, Fus-co N, Mazzarella L, Criscitiello C, Esposito A, Curigliano G. Pharma-cological management of male breast cancer. Expert Opin Phar-macother. 2020; 21: 1493–1504. https://doi.org/10.1080/14656566.2020.1763305
Lewis-Smith, H. Breast cancer or chest cancer? The impact of li-ving with a “woman’s disease”. J aesthet nurs. 2016; 5: 240–241. doi:10.12968/joan.2016.5.5.240
Reinisch M, Seiler S, Hauzenberger T, Kamischke A, Schmatloch S, Stri-ttmatter HJ, Loibl S. Efficacy of endocrine therapy for the treatment of breast cancer in men: results from the MALE phase 2 randomized clinical trial. JAMA Oncol. 2021; 7: 565-572. https://doi.org/10.1001/jamaoncol.2020.7442
Sang G, Pan H, Lu C, Sun R, Zha X, Wang S, Zhu D. Clinical features and prognostic factors of male breast cancer vs. female breast cancer. Transl Cancer Res. 2021; 10: 2199–2209. https://doi.org/10.21037/tcr-21-1
Wibowo E, Pollock PA, Hollis N, Wassersug RJ. Tamoxifen in men: a re-view of adverse events. Andrology. 2016; 4: 776–788. https://doi.org/10.1111/andr.12197
Kim SH, Kim YS. Ultrasonographic and Mammographic Findings of Male Breast Disease. J Ultrasound. 2019; 38: 243–252. https://doi.org/10.1002/jum.14665
Ruddy K, Ferzoco R. Optimal delivery of male breast cancer follow-up care: improving outcomes. Breast Cancer: Targets Ther. 2015; 14: 371. doi:10.2147/bctt.s75630
Thompson E, Haydock A. Men’s Lived Experiences with Breast Cancer: The Double Consciousness of Marginal Men. Sex Roles. 2019; 82: 28–43. doi:10.1007/s11199-019-01039-7
Darkeh MHSE, Azavedo E. Male breast cancer clinical features, risk factors, and current diagnostic and therapeutic approaches. Int J Clin Med. 2014; 5: 1068–1086. http://dx.doi.org/10.4236/ijcm.2014.517138
Hwang EJ, Cha JH. [A Review on Gynecomastia and Male Breast Cancer for Radiologists]. J Korean Soc Radio. 2020; 81: 1096–1108. https://doi.org/10.3348/jksr.2019.0203
Eggemann H, Brucker C, Schrauder M, Thill M, Flock F, Reinisch M, Costa SD, Ignatov A. Survival benefit of tamoxifen in male breast cancer: prospec-tive cohort analysis. Br J Cancer. 2020; 123: 33–37. https://doi.org/10.1038/s41416-020-0857-z
Jain S, Gradishar WJ. Male breast cancer. Evanston: Elsevier; 2018.28. Leon-Ferre RA, Giridhar KV, Hieken TJ, Mutter RW, Couch FJ, Jimenez RE, Ruddy KJ. A contemporary review of male breast cancer: current eviden-ce and unanswered questions. Cancer Metastasis Rev. 2018; 37: 599-614. doi:10.1007/s10555-018-9761-x
Sabih QA, Young J, Takabe K. Management of Male Breast Cancer: The Journey so Far and Future Directions. World J Oncol. 2021; 12: 206–213. https://doi.org/10.14740/wjon1418
Charalambous A, Giannakopoulou M, Bozas E, Paikousis L. Parallel and se-rial mediation analysis between pain, anxiety, depression, fatigue and nau-sea, vomiting and retching within a randomised controlled trial in patients with breast and prostate cancer. BMJ Open. 2019; 9: e026809. https://doi.org/10.1136/bmjopen-2018-026809
Nikolić D, Granić M, Ivanović N, Zdravković D, Nikolić A, Stanimirović V, Zdravković M, Dikić S, Nikolić M, Djordjević M. Breast cancer and its impact in male transsexuals. Breast Cancer Res Treat. 2018; 171: 565–569. https://doi.org/10.1007/s10549-018-4875-y
Walker RK, Ehrlich O, Berry DL. Male breast cancer survivors’ pers-pectives on the adequacy of their survivorship care. Innovation in Aging. 2018; 1: (2): 418–8. https://doi:10.1093/geroni/igy023.1563
American Cancer Society. Cómo el cáncer y el tratamiento pueden afec-tar la sexualidad. Am Can Soc [serial on the Internet].2020 Jan-Mar [cited 2022 Nov 5]; 1 (1): [about 24 p.]. Avai-lable from: https://www.cancer.org/es/tratamiento/tratamientos-y-efectos-se-cundarios/efectos-secundarios-fisicos/efectos-secundarios-sobre-la-ferti-lidad-y-la-sexualidad/como-el-can-cer-afecta-la-sexualidad.html
Campo-Arias A, Herazo E. Noveda-des, críticas y propuestas al DSM-5: el caso de las disfunciones sexua-les, la disforia de género y los tras-tornos parafílicos. Rev Colomb Psi-quiatr. 2016;47:56-64. doi:10.1016/j.rcp.2016.08.008.
Marina P, García-Portilla MP, Jimé-nez L, Palicioc L, Trabajo P, Bobes J. Función sexual en pacientes de-primidos: Relación entre síntomas depresivos y disfunción sexual. Rev Neuropsiquiátr. 2013; 76: 3.
Bettahar K, Pinton A. Agonistas de la hormona liberadora de gonadotropi-nas (GnRH). EMC - Ginecología-Obs-tetricia. 2019; 55: 1-9. https://doi.org/10.1016/S1283-081X(19)42001-8.
Oncology Nurse Advisor. Optimal De-livery of Male Breast Cancer Follow-up Care: Improving Outcomes [Internet]. Oncology Nurse Advisor. 2015 [cited 2023 Mar 14]. Available from: https://www.oncologynurseadvisor.com/home/cancer-types/breast-cancer/optimal-delivery-of-male-breast-can-cer-follow-up-care-improving-outco-mes/4/